Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Accumulated Expenses of $1.2 million for Q1 2026, down 40.7% year-over-year from $2.1 million in Q1 2025, and down 67.04% quarter-over-quarter from $3.7 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 40.7% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 40.7% YoY), while the FY2025 annual figure was $3.7 million, up 22.11% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $1.2 million, down from $3.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $21.0 million in Q2 2022, with the low at $349000.0 in Q3 2023.
- The 5-year median for Accumulated Expenses is $1.9 million (2022), against an average of $2.9 million.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 1474.21% in 2022, then tumbled 97.23% in 2023.
- Lineage Cell Therapeutics' Accumulated Expenses stood at $3.8 million in 2022, then dropped by 18.52% to $3.1 million in 2023, then declined by 1.83% to $3.1 million in 2024, then gained by 22.11% to $3.7 million in 2025, then slumped by 67.04% to $1.2 million in 2026.
- Business Quant data shows LCTX's Accumulated Expenses at $1.2 million in Q1 2026, $3.7 million in Q4 2025, and $486000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.85 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 3.74 Mn |
| Sep 30, 2025 | 486,000.00 |
| Jun 30, 2025 | 793,000.00 |
| Mar 31, 2025 | 2.08 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 384,000.00 |
| Jun 30, 2024 | 2.22 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Sep 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 581,000.00 |
| Mar 31, 2023 | 404,000.00 |
| Dec 31, 2022 | 3.83 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 21.00 Mn |
| Mar 31, 2022 | 1.59 Mn |
| Dec 31, 2021 | 22.09 Mn |
| Sep 30, 2021 | 1.54 Mn |